Heparan sulfate signaling in cancer

Trends in Biochemical Sciences

Volumn 39, Issue 6, 2014, Pages 277-288

  Knelson, Erik H ^a   Nee, Jasmine C ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heparan sulfate; Heparanase; Heparin; Metastasis; Sulfatase; Sulfyltransferase

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GROWTH DIFFERENTIATION FACTOR; HEPARAN SULFATE; HEPARANASE; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 4; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEOHEPARAN SULFATE; SCATTER FACTOR; SELECTIN; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; SULFATASE; SULFOTRANSFERASE; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; LUNG METASTASIS; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; HEPARITIN SULFATE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84901202683     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.03.001     Document Type: Review

References (136)

1. Howell W.H., Holt E. Two new factors in blood coagulation-heparin and pro-antithrombin. Am. J. Physiol. 1918, 47:328-341.
2. Linker A., et al. Heparitin sulfate. Biochim. Biophys. Acta 1958, 29:443-444.
3. Olson S.T., Shore J.D. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. J. Biol. Chem. 1981, 256:11065-11072.
4. Rabenstein D.L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 2002, 19:312-331.
5. Iozzo R.V. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J. Clin. Invest. 2001, 108:165-167.
6. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem. Rev. 2005, 105:2745-2764.
7. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71:435-471.
8. Mythreye K., Blobe G.C. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell. Signal. 2009, 21:1548-1558.
9. Kirkbride K.C., et al. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem. Sci. 2005, 30:611-621.
10. Cardin A.D., Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989, 9:21-32.
11. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002, 41:391-412.
12. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
13. Spivak-Kroizman T., et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79:1015-1024.
14. Gatza C.E., et al. Roles for the type III TGF-β receptor in human cancer. Cell. Signal. 2010, 22:1163-1174.
15. Dong M., et al. The type III TGF-β receptor suppresses breast cancer progression. J. Clin. Invest. 2007, 117:206-217.
16. Matsuda K., et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61:5562-5569.
17. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
18. Khotskaya Y.B., et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 2009, 284:26085-26095.
19. Aikawa T., et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 2008, 118:89-99.
20. Williamson D., et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 2007, 67:57-65.
21. Park H., et al. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J. Biol. Chem. 2002, 277:29730-29736.
22. Sun M., et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene 2013, 10.1038/onc.2013.328.
23. Oh T., et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagn. 2013, 15:498-507.
24. Maeda T., et al. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25:1408-1412.
25. Yang Y., et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
26. Knelson E.H., et al. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J. Clin. Invest. 2013, 123:4786-4798.
27. Knelson E.H., et al. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J. Clin. Invest. 2014, in press.
28. Cheng W., et al. Glypican-3-mediated oncogenesis involves the insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29:1319-1326.
29. Zittermann S.I., et al. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int. J. Cancer 2010, 126:1291-1301.
30. Kleeff J., et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 1998, 102:1662-1673.
31. Harris N.C., et al. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J. Biol. Chem. 2013, 288:8176-8186.
32. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
33. Sharma B., et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Invest. 1998, 102:1599-1608.
34. Goyal A., et al. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 2011, 286:25947-25962.
35. O'Reilly M.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
36. Seppinen L., Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol. 2011, 30:83-92.
37. Rong B., et al. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J. Surg. Oncol. 2012, 10:170.
38. Bagri A., et al. Neuropilins in tumor biology. Clin. Cancer Res. 2009, 15:1860-1864.
39. Pan Q., et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67.
40. Epis M.R., et al. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J. Neurooncol. 2014, 116:67-75.
41. Lee E., et al. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 2013, 15:112-124.
42. Shintani Y., et al. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J. 2006, 25:3045-3055.
43. Marcum J.A., et al. Microvascular heparin-like species with anticoagulant activity. Am. J. Physiol. 1983, 245:H725-H733.
44. Kelton J.G., et al. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N. Engl. J. Med. 2013, 368:737-744.
45. Battinelli E.M., et al. Anticoagulation inhibits tumor cell mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014, 123:101-112.
46. Liu W., et al. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J. Biol. Chem. 1998, 273:22825-22832.
47. Williams K., et al. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp. Biol. Med. (Maywood) 2013, 238:324-338.
48. Jackson D.G., et al. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Biol. 1995, 128:673-685.
49. Orian-Rousseau V., et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16:3074-3086.
50. Munchar M.J., et al. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours. Pathology 2003, 35:125-129.
51. Borsig L., et al. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia 2011, 13:445-452.
52. Bendas G., Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol. 2012, 2012:676731.
53. Mennerich D., et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur. J. Cancer 2004, 40:1373-1382.
54. Contreras H.R., et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer. Urol. Oncol. 2010, 28:534-540.
55. Nikolova V., et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
56. Ding K., et al. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 2005, 171:729-738.
57. Koliopanos A., et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001, 61:4655-4659.
58. Theodoro T.R., et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 2007, 9:504-510.
59. Inki P., et al. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix. J. Pathol. 1994, 172:349-355.
60. Inki P., Jalkanen M. The role of syndecan-1 in malignancies. Ann. Med. 1996, 28:63-67.
61. Nackaerts K., et al. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int. J. Cancer 1997, 74:335-345.
62. Xiang Y.Y., et al. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
63. Bandyopadhyay A., et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 2002, 62:4690-4695.
64. Tagalakis V., et al. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat. Rev. 2007, 33:358-368.
65. Zhang J., et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 2013, 68:442-450.
66. Stevenson J.L., et al. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 2005, 11:7003-7011.
67. Hossain M.M., et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology 2010, 20:175-186.
68. Smorenburg S.M., Van Noorden C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 2001, 53:93-105.
69. 3 mediated adhesion of melanoma cells to platelets in vitro and in vivo. Int. J. Cancer 2009, 125:2058-2065.
70. Hostettler N., et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007, 21:3562-3572.
71. Rao N.V., et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am. J. Physiol. Cell Physiol. 2010, 299:C97-C110.
72. Vlodavsky I., et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994, 14:290-302.
73. Lundin L., et al. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 2000, 275:24653-24660.
74. Feng M., et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E1083-E1091.
75. Zhu A.X., et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2013, 19:920-928.
76. Tyrrell D.J., et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol. 1999, 46:151-208.
77. Biroccio A., et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat. Cell Biol. 2013, 15:818-828.
78. Chen J.L., et al. Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo. Gastroenterol. Res. Pract. 2012, 2012:752940.
79. Zhang L., Esko J.D. Amino acid determinants that drive heparan sulfate assembly in a proteoglycan. J. Biol. Chem. 1994, 269:19295-19299.
80. Hwang J.A., et al. Epigenetic inactivation of heparan sulfate (glucosamine) 3-o-sulfotransferase 2 in lung cancer and its role in tumorigenesis. PLoS ONE 2013, 8:e79634.
81. Ferguson B.W., Datta S. Role of heparan sulfate 2-o-sulfotransferase in prostate cancer cell proliferation, invasion, and growth factor signaling. Prostate Cancer 2011, 2011:893208.
82. Pollari S., et al. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol. Cancer Res. 2012, 10:597-604.
83. Song K., et al. Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer. Cancer Biol. Ther. 2011, 12:388-398.
84. Vlodavsky I., Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108:341-347.
85. Lai J.P., et al. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J. Gastrointest. Cancer 2008, 39:149-158.
86. Peterson S.B., Liu J. Multi-faceted substrate specificity of heparanase. Matrix Biol. 2013, 32:223-227.
87. Khasraw M., et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann. Oncol. 2010, 21:1302-1307.
88. Liu C.J., et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J. Hepatol. 2009, 50:958-968.
89. Ritchie J.P., et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 2011, 17:1382-1393.
90. Zhou H., et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 2011, 6:e21106.
91. Hammond E., et al. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS ONE 2012, 7:e52175.
92. Ostapoff K.T., et al. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol. Cancer Ther. 2013, 12:1190-1201.
93. Lai J.P., et al. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008, 4:803-814.
94. Lai J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47:1211-1222.
95. Rosen S.D., Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin. Ther. Targets 2010, 14:935-949.
96. Phillips J.J., et al. Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma. J. Clin. Invest. 2012, 122:911-922.
97. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
98. Gherardi E., et al. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12:89-103.
99. Heldin C.H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. 2013, 11:97.
100. Sahebjam S., et al. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 2012, 17:1090-1099.
101. Roberts E., et al. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer 2013, 2013:418340.
102. Guillemot F., Zimmer C. From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron 2011, 71:574-588.
103. Boon M.R., et al. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev. 2011, 22:221-229.
104. Irie A., et al. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem. Biophys. Res. Commun. 2003, 308:858-865.
105. Paine-Saunders S., et al. Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J. Biol. Chem. 2002, 277:2089-2096.
106. Witt R.M., et al. Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation. J. Biol. Chem. 2013, 288:26275-26288.
107. Cotman S.L., et al. Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin. Exp. Cell Res. 1999, 249:54-64.
108. Aviezer D., et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79:1005-1013.
109. Mongiat M., et al. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J. Biol. Chem. 2000, 275:7095-7100.
110. Kawashima H., et al. Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1. J. Biol. Chem. 2003, 278:13069-13076.
111. Jones M., et al. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J. Biol. Chem. 2000, 275:7964-7974.
112. Marzioni D., et al. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int. J. Immunopathol. Pharmacol. 2009, 22:627-638.
113. Park H., et al. Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells. Cancer Res. 2005, 65:9899-9905.
114. Popovic A., et al. Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis. 2010, 13:78-82.
115. Yamanaka K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73:389-394.
116. Boily G., et al. In vivo footprinting analysis of the glypican 3 (GPC3) promoter region in neuroblastoma cells. Biochim. Biophys. Acta 2007, 1769:182-193.
117. Esheba G.E., et al. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am. J. Surg. Pathol. 2008, 32:600-607.
118. Lin Q., et al. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med. Oncol. 2012, 29:663-669.
119. Powell C.A., et al. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest 2002, 121:6S-7S.
120. Li Y., et al. The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer. Oncol. Lett. 2013, 6:1565-1572.
121. Li Y., et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010, 11:321-330.
122. Batmunkh E., et al. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum. Pathol. 2007, 38:1508-1515.
123. Tatrai P., et al. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab. Invest. 2006, 86:1149-1160.
124. Warth A., et al. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol. 2004, 107:311-318.
125. Kadenhe-Chiweshe A., et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol. Cancer Res. 2008, 6:1-9.
126. Gronborg M., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5:157-171.
127. Fernandez-Vega I., et al. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer. BMC Cancer 2013, 13:24.
128. Davies E.J., et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 2004, 10:5178-5186.
129. Franses J.W., et al. Stromal endothelial cells directly influence cancer progression. Sci. Transl. Med. 2011, 3:66ra65.
130. Iozzo R.V., et al. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol. Cells 2009, 27:503-513.
131. Gatza C.E., et al. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia 2011, 13:758-770.
132. Bernabeu C., et al. The emerging role of TGF-β superfamily coreceptors in cancer. Biochim. Biophys. Acta 2009, 1792:954-973.
133. Lambert K.E., et al. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol. Biol. Cell 2011, 22:1463-1472.
134. Hanks B.A., et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J. Clin. Invest. 2013, 123:3925-3940.
135. Fakhari M., et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 2002, 94:258-263.
136. Nasarre P., et al. Neuropilin-2 is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Res. 2013, 73:7111-7121.